Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL

Urology

Volumn 61, Issue 4, 2003, Pages 760-764

  Ito, Kazuto ^a   Yamamoto, Takumi ^a   Ohi, Masaru ^a   Kurokawa, Kohei ^a   Suzuki, Kazuhiro ^a   Yamanaka, Hidetoshi ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; RISK ASSESSMENT;

EID: 0037381702     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(02)02427-5     Document Type: Article

References (16)

1. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease a prospective multicenter trial. JAMA. 279:1998;1542-1547.
2. Cangh P.J.V., Nayer P.D., Vischer L.D., et al. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnosis gray zone of 1.8 to 10 ng/mL total PSA. Urology. 48:1996;67-70.
3. Kikuchi E., Nakashima J., Ishibashi M., et al. Prostate specific antigen adjusted for transition zone volume the most powerful method for detecting prostate carcinoma. Cancer. 89:2000;842-849.
4. Catalona W.J., Partin A.W., Slawin K.M., et al. Percentage of free PSA in black versus white men for detection and staging of prostate cancer a prospective multicenter clinical trial. Urology. 55:2000;372-376.
5. Djavan B., Zlotta A.R., Remzi M., et al. Total and transition zone prostate volume and age how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology. 54:1999;846-852.
6. Ito K., Ichinose Y., Kubota Y., et al. Clinicopathological features of prostate cancer detected by transrectal ultrasonography-guided systematic six-sextant biopsy. Int J Urol. 4:1997;474-479.
7. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men. J Urol. 151:1994;1283-1290.
8. Hummerer P., Huland H. Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol. 151:1994;99-102.
9. Pearson J.D., Luderer A.A., Metter E.J., et al. Longitudinal analysis of serial measurement of free and total PSA among men with and without prostate cancer. Urology. 48:1996;4-9.
10. Kano S., Ishibashi M. How degree are the inter-method deviations reduced in total PSA assay? Report of 2000 survey. Jpn J Urol Surg. 14:2001;433-439.
11. Djavan B., Zlotta A., Remzi M., et al. Optimal predictors of prostate cancer on repeat prostate biopsy a prospective study of 1,051 men. J Urol. 163:2000;1144-1148.
12. O'Dowd G.J., Miller M.C., Orozco R., et al. Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology. 55:2000;553-558.
13. Fowler J.E. Jr, Bigler S.A., Miles D., et al. Predictors of first repeat biopsy cancer detection with suspected local stage prostate cancer. J Urol. 163:2000;813-818.
14. Arcangeli C.G., Humphrey P.A., Smith D.S., et al. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology. 51:1998;558-564.
15. Carter H.B., Partin A.W., Luderer A.A., et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology. 49:1997;379-384.
16. Pannek J., Rittenhouse H.G., Chan D.W., et al. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol. 159:1998;1238-1242.